Related Experiment Video
Updated: Aug 14, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond
1Department of Basic Chemistry, Merck Research Laboratories, Merck & Co. Inc. P.O. Box 2000, Rahway, New Jersey 07065, USA. brian_jones@merck.com
Medicinal Research Reviews
|October 19, 2001
Summary
Peroxisome proliferator-activated receptors (PPARs) are key transcription factors regulating metabolism. This report introduces the PPAR field and early PPAR ligands involved in metabolic regulation.
Area of Science:
- Biochemistry
- Molecular Biology
- Metabolic Regulation
Background:
- Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate gene expression.
- PPARs play a crucial role in metabolic homeostasis, including lipid and glucose metabolism.
- Dysregulation of PPARs is implicated in various metabolic diseases.
Purpose of the Study:
- To provide a concise introduction to the field of PPARs.
- To highlight the role of PPARs as ligand-modulated transcription factors.
- To present an overview of early PPAR ligands and their significance.
Main Methods:
- Literature review of PPAR research.
- Analysis of early PPAR ligand structures and functions.
- Discussion of PPARs' role in metabolic regulation.
Main Results:
- PPARs are critical regulators of metabolic processes.
- Ligand binding modulates PPAR transcriptional activity.
- Early PPAR ligands paved the way for understanding PPAR function.
Conclusions:
- PPARs are central players in metabolic control.
- The study of PPAR ligands is essential for understanding metabolic pathways.
- Further research into PPARs and their ligands holds therapeutic potential for metabolic disorders.
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.